Read More

Billions On The Move: Tracking Market Cap Changes In Top Cannabis Firms After DEA Rescheduling Announcement

Tuesday's announcement that the DEA is moving towards rescheduling cannabis from Schedule I to Schedule III, has already injected billions into the publicly traded market for cannabis companies.

ACB

Read More

TransMedics Stock Skyrockets, Analysts Call It ‘One Of The Best Organic Growth Stories’

TransMedics shines with Q1 EPS at $0.35, and sales soared to $96.9 million. Fiscal 2024 revenue outlook raised to $390 million-$400 million. Analysts hail TransMedics' organic growth and strong market position, praising its innovative solutions and promising prospects.

TMDX